California Public Employees Retirement System Sells 4,681 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

California Public Employees Retirement System lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 164,712 shares of the biopharmaceutical company's stock after selling 4,681 shares during the quarter. California Public Employees Retirement System owned about 0.15% of Intra-Cellular Therapies worth $13,757,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 240 shares during the period. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at $96,000. Wilmington Savings Fund Society FSB purchased a new position in Intra-Cellular Therapies during the 3rd quarter worth $97,000. Quarry LP grew its stake in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock worth $132,000 after buying an additional 1,300 shares during the last quarter. Finally, Barlow Wealth Partners Inc. purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at about $184,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

Intra-Cellular Therapies Price Performance

NASDAQ:ITCI remained flat at $131.87 during mid-day trading on Thursday. The stock has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The company's 50 day simple moving average is $130.10 and its two-hundred day simple moving average is $103.37.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Piper Sandler restated a "neutral" rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Mizuho cut Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price objective for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Eleven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.